A Pilot Study of DKN-01 and Lenalidomide (Revlimid)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Pilot Study of DKN-01 and Lenalidomide (Revlimid)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs DKN 01 (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors HealthCare Pharmaceuticals Inc; Leap Therapeutics
  • Most Recent Events

    • 01 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 31 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 16 May 2013 Planned initiation date changed from 1 Jun 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top